Comparison of Long-Term Outcome for AML Patients Alive Free of Disease 2 Years after Allogeneic Hematopoietic Cell Transplantation with Umbilical Cord Blood versus Unrelated Donor: A Study from the ALWP of the EBMT

By
Justin.choi
-
0
54
Scientists performed a landmark study comparing long-term outcomes in acute myeloid leukemia patients alive and disease-free two years after transplantation who received grafts from either cord blood transplantation or unrelated donors.
[Bone Marrow Transplantation]
6445218 {6445218:6JTQUIQT} 1 apa 50 default 1 164498 https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%226JTQUIQT%22%2C%22library%22%3A%7B%22id%22%3A6445218%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Baron%20et%20al.%22%2C%22parsedDate%22%3A%222021-07-10%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BBaron%2C%20F.%2C%20Ngoya%2C%20M.%2C%20Labopin%2C%20M.%2C%20Cornelissen%2C%20J.%20J.%2C%20Ganser%2C%20A.%2C%20Forcade%2C%20E.%2C%20Sengeloev%2C%20H.%2C%20Soci%26%23xE9%3B%2C%20G.%2C%20Blaise%2C%20D.%2C%20Bornh%26%23xE4%3Buser%2C%20M.%2C%20Valerius%2C%20T.%2C%20Reinhardt%2C%20H.%20C.%2C%20Kr%26%23xF6%3Bger%2C%20N.%2C%20Ruggeri%2C%20A.%2C%20Nagler%2C%20A.%2C%20%26amp%3B%20Mohty%2C%20M.%20%282021%29.%20Comparison%20of%20long-term%20outcome%20for%20AML%20patients%20alive%20free%20of%20disease%202%20years%20after%20allogeneic%20hematopoietic%20cell%20transplantation%20with%20umbilical%20cord%20blood%20versus%20unrelated%20donor%3A%20a%20study%20from%20the%20ALWP%20of%20the%20EBMT.%20%26lt%3Bi%26gt%3BBone%20Marrow%20Transplantation%26lt%3B%5C%2Fi%26gt%3B%2C%201%26%23x2013%3B7.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41409-021-01387-7%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41409-021-01387-7%26lt%3B%5C%2Fa%26gt%3B%20%26lt%3Ba%20title%3D%26%23039%3BCite%20in%20RIS%20Format%26%23039%3B%20class%3D%26%23039%3Bzp-CiteRIS%26%23039%3B%20data-zp-cite%3D%26%23039%3Bapi_user_id%3D6445218%26amp%3Bitem_key%3D6JTQUIQT%26%23039%3B%20href%3D%26%23039%3Bjavascript%3Avoid%280%29%3B%26%23039%3B%26gt%3BCite%26lt%3B%5C%2Fa%26gt%3B%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Comparison%20of%20long-term%20outcome%20for%20AML%20patients%20alive%20free%20of%20disease%202%20years%20after%20allogeneic%20hematopoietic%20cell%20transplantation%20with%20umbilical%20cord%20blood%20versus%20unrelated%20donor%3A%20a%20study%20from%20the%20ALWP%20of%20the%20EBMT%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Baron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maud%22%2C%22lastName%22%3A%22Ngoya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Myriam%22%2C%22lastName%22%3A%22Labopin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan%20J.%22%2C%22lastName%22%3A%22Cornelissen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnold%22%2C%22lastName%22%3A%22Ganser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edouard%22%2C%22lastName%22%3A%22Forcade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Henrik%22%2C%22lastName%22%3A%22Sengeloev%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%5Cu00e9rard%22%2C%22lastName%22%3A%22Soci%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Didier%22%2C%22lastName%22%3A%22Blaise%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%22%2C%22lastName%22%3A%22Bornh%5Cu00e4user%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Valerius%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hans%20Christian%22%2C%22lastName%22%3A%22Reinhardt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolaus%22%2C%22lastName%22%3A%22Kr%5Cu00f6ger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Annalisa%22%2C%22lastName%22%3A%22Ruggeri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnon%22%2C%22lastName%22%3A%22Nagler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mohamad%22%2C%22lastName%22%3A%22Mohty%22%7D%5D%2C%22abstractNote%22%3A%22Since%20cord%20blood%20transplantation%20%28CBT%29%20has%20been%20associated%20with%20high%20graft-versus-leukemia%20effects%20and%20a%20low%20incidence%20of%20chronic%20graft-versus-host%20disease%20%28GVHD%29%2C%20we%20hypothesized%20that%20long-term%20outcomes%20might%20be%20better%20in%20CBT%20patients%20than%20in%20those%20given%20grafts%20from%20unrelated%20donors%20%28UD%29.%20Therefore%2C%20we%20performed%20a%20landmark%20study%20comparing%20long-term%20outcomes%20in%20acute%20myeloid%20leukemia%20%28AML%29%20patients%20alive%20and%20disease-free%202%20years%20after%20transplantation%20who%20received%20grafts%20from%20either%20CBT%20or%20UD.%20A%20total%20of%20364%20CBT%20recipients%2C%202648%20UD%2010%5C%2F10%20patients%20and%20681%20patients%20given%20grafts%20from%20UD%209%5C%2F10%20were%20included.%20Median%20follow-up%20was%206.0%20years.%20Five-year%20leukemia-free%20survival%20%28LFS%29%20from%20transplantation%20was%2086%25%20in%20CBT%20patients%2C%2084%25%20in%20UD%2010%5C%2F10%20patients%20%28P%5Cu2009%3D%5Cu20090.36%29%20and%2084%25%20in%20UD%209%5C%2F10%20patients%20%28P%5Cu2009%3D%5Cu20090.86%29.%20On%20multivariate%20analysis%2C%20donor%20type%20had%20no%20impact%20on%20LFS.%20Similarly%2C%20no%20impact%20of%20donor%20type%20was%20observed%20on%20relapse%20incidence%20or%20non-relapse%20mortality.%20Factors%20associated%20with%20poorer%20LFS%20on%20multivariate%20analysis%20included%20higher%20age%20at%20transplantation%20%28P%5Cu2009%26lt%3B%5Cu20090.001%29%2C%20male%20gender%20%28P%5Cu2009%26lt%3B%5Cu20090.001%29%2C%20second%20complete%20remission%20%28CR2%29%20versus%20CR1%20%28P%5Cu2009%3D%5Cu20090.05%29%2C%20secondary%20AML%20%28P%5Cu2009%3D%5Cu20090.01%29%2C%20antecedent%20of%20chronic%20GVHD%20%28P%5Cu2009%26lt%3B%5Cu20090.001%29%20and%20poor-risk%20cytogenetics%20%28P%5Cu2009%3D%5Cu20090.01%29.%20In%20conclusion%2C%20our%20study%20shows%20that%20long-term%20outcome%20for%20AML%20patients%20in%20CR%20two%20years%20after%20transplantation%20is%20not%20impacted%20by%20donor%20type.%22%2C%22date%22%3A%222021-07-10%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41409-021-01387-7%22%2C%22ISSN%22%3A%221476-5365%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.nature.com%5C%2Farticles%5C%2Fs41409-021-01387-7%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-07-13T18%3A31%3A59Z%22%7D%7D%5D%7D
Baron, F., Ngoya, M., Labopin, M., Cornelissen, J. J., Ganser, A., Forcade, E., Sengeloev, H., Socié, G., Blaise, D., Bornhäuser, M., Valerius, T., Reinhardt, H. C., Kröger, N., Ruggeri, A., Nagler, A., & Mohty, M. (2021). Comparison of long-term outcome for AML patients alive free of disease 2 years after allogeneic hematopoietic cell transplantation with umbilical cord blood versus unrelated donor: a study from the ALWP of the EBMT. Bone Marrow Transplantation, 1–7. https://doi.org/10.1038/s41409-021-01387-7 Cite
Abstract